Basics of PD-1 in self-tolerance, infection, and cancer immunity

Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report

(2015) Juan Martin-Liberal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Response to Comment on Hughes et al. An Early Pregnancy HbA1c≥5.9% (41 mmol/mol) Is Optimal for Detecting Diabetes and Identifies Women at Increased Risk of Adverse Pregnancy Outcomes. Diabetes Care 2014;37:2953–2959

(2015) Ruth C.E. Hughes et al.   DIABETES CARE

Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+T cells

(2015) Pamela M. Odorizzi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 Suppresses Protective Immunity toStreptococcus pneumoniaethrough a B Cell–Intrinsic Mechanism

(2015) Jerome T. McKay et al.   JOURNAL OF IMMUNOLOGY

Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer

(2015) Aaron I. Loochtan et al.   MUSCLE & NERVE

Tuning of Antigen Sensitivity by T Cell Receptor-Dependent Negative Feedback Controls T Cell Effector Function in Inflamed Tissues

(2014) Tetsuya Honda et al.   IMMUNITY

Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice

(2014) J. A. Lucas et al.   JOURNAL OF IMMUNOLOGY

Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival

(2013) Neil Romberg et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

(2013) Taku Okazaki et al.   NATURE IMMUNOLOGY

Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response

(2013) Y. Rui et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-1 Dependent Exhaustion of CD8+ T Cells Drives Chronic Malaria

(2013) Joshua M. Horne-Debets et al.   Cell Reports

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

(2012) Tadashi Yokosuka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family

(2011) Hélène Bour-Jordan et al.   IMMUNOLOGICAL REVIEWS

IFN-  Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity

(2011) S. Terawaki et al.   JOURNAL OF IMMUNOLOGY

T Cells from Programmed Death-1 Deficient Mice Respond Poorly to Mycobacterium tuberculosis Infection

(2011) Sultan Tousif et al.   PLoS One

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

PD-1 deficiency results in the development of fatal myocarditis in MRL mice

(2010) Jian Wang et al.   INTERNATIONAL IMMUNOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

CD4 T Cells Promote Rather than Control Tuberculosis in the Absence of PD-1-Mediated Inhibition

(2010) D. L. Barber et al.   JOURNAL OF IMMUNOLOGY

Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis

(2010) E. Lazar-Molnar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo

(2009) S. Chikuma et al.   JOURNAL OF IMMUNOLOGY

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal

(2009) Brian T Fife et al.   NATURE IMMUNOLOGY